Prof. Kevin Outterson is the founding Executive Director of CARB-X, the world’s leading public-private partnership that accelerates the early-stage development of innovative products to prevent, diagnose, and treat bacterial infections globally. CARB-X has supported more than 100 R&D projects around the world. Eighteen of these projects have already reached or surpassed first-in-human clinical trials, including two products already on the market. In 2020, CARB-X was awarded the Innovating for Impact Partnership Award by the Global Health Technologies Coalition (GHTC). CARB-X funders include the governments of the United States (BARDA & NIAID), Germany (BMBF), United Kingdom (GAMRIF), Canada (PHAC), and Japan (MHLW), plus Wellcome, the Novo Nordisk Foundation, and the Bill & Melinda Gates Foundation.
Prof. Outterson is also the Austin B. Fletcher Professor of Law at Boston University, where he co-directs the Health Law Program. Prof. Outterson has published around 100 articles and book chapters on healthcare law, with a focus on incentive problems related to pharmaceutical products, including push and pull incentives for antimicrobials. Prof. Outterson was given the 2015 Leadership Award by the Alliance for the Prudent Use of Antibiotics for his research and advocacy work.
